These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30937664)

  • 1. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
    Takeuchi M; Kawakubo H; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2019 Jul; 26(7):2081-2089. PubMed ID: 30937664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy.
    Ohkura Y; Shindoh J; Ueno M; Iizuka T; Udagawa H
    Ann Surg Oncol; 2018 Aug; 25(8):2428-2433. PubMed ID: 29564587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
    Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
    Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.
    Wu YY; Dai L; Yang YB; Yan WP; Cheng H; Fan MY; Gao YM; Chen KN
    Ann Surg Oncol; 2024 Aug; 31(8):5047-5054. PubMed ID: 38172446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
    Ilson D; Lordick F
    Lancet Oncol; 2018 Oct; 19(10):1285-1286. PubMed ID: 30528077
    [No Abstract]   [Full Text] [Related]  

  • 10. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
    Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
    BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Yu YK; Meng FY; Wei XF; Chen XK; Li HM; Liu Q; Li CJ; Xie HN; Xu L; Zhang RX; Xing W; Li Y
    J Thorac Cardiovasc Surg; 2024 Aug; 168(2):417-428.e3. PubMed ID: 38246339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
    Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
    World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS).
    Toxopeus E; van der Schaaf M; van Lanschot J; Lagergren J; Lagergren P; van der Gaast A; Wijnhoven B
    Ann Surg Oncol; 2018 Aug; 25(8):2441-2448. PubMed ID: 29948420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia.
    Kuo YH; Chien YW; Chen PR; Feng CL; Li CC; Chien CR
    World J Surg Oncol; 2019 Dec; 17(1):222. PubMed ID: 31856840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Doses of Neoadjuvant Radiation for Esophageal Cancer Do Not Affect the Pathologic Complete Response Rate or Survival: A Propensity-Matched Analysis.
    Worrell SG; Towe CW; A Dorth J; Machtay M; Perry Y; Linden PA
    Ann Surg Oncol; 2020 Feb; 27(2):500-508. PubMed ID: 31571054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer.
    Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Fukuda K; Nakamura R; Suda K; Wada N; Takeuchi H; Kitagawa Y
    J Gastrointest Surg; 2018 Nov; 22(11):1881-1889. PubMed ID: 29980971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.